Genzyme related Press Releases

Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients Genzyme and Isis Read more...

FOVEA Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With GENZYME Corporation PARIS, Nov. 27  -- FOVEA Pharmaceuticals SA. announced today that they have entered into a Read more...

Genzyme Corporation Receives FDA Response Letter on Synvisc-One(TM) Approval in U.S. to be Delayed CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has Read more...

Genzyme Corporation's Epicel Wins Marketing Approval for Severe Burn Victims CAMBRIDGE, Mass., Oct. 29 -- Genzyme Corporation announced today that the U.S. Food and Drug Administration (FDA) has Read more...

Bioenvision Shareholders Approve Acquisition by Genzyme Corporation Genzyme Corporation and Bioenvision announced this afternoon that Bioenvision stockholders have voted to approve the acquisition Read more...

FDA Approves Genzyme's Renvela for Dialysis Patients Genzyme today announced that the U.S. Food and Drug Administration has granted marketing approval for Renvela™ (sevelamer carbonate) for the Read more...

FDA Approves Genzyme's Renvela for Dialysis Patients Genzyme today announced that the U.S. Food and Drug Administration has granted marketing approval for Renvela™ (sevelamer carbonate) for the Read more...

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab Compared to Rebif Genzyme Corporation today announced that top-line, three-year data from a Read more...

Henri A. Termeer Chairman, President and CEO Genzyme Corporation 500 Kendall Street Cambridge, MA 02142 USA Dear Mr. Termeer: The Food and Drug Administration (FDA) conducted an inspection of Read more...

Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share Genzyme Corporation confirmed today that it will not change its purchase price for Bioenvision at $5.60 in cash per Read more...